Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 4Unknown 2Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Neoplasms 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Non-Muscle Invasive Bladder Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 16daratumumab 14Bortezomib 11Lenalidomide 9pomalidomide 7Calcium Dobesilate 6isatuximab 4belantamab mafodotin 4Cyclophosphamide 4carfilzomib 3Melphalan 3tocilizumab 2iberdomide 2dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Specimen Handling 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2Biopsy 2zanubrutinib 1trametinib 1talquetamab 1selinexor 1pembrolizumab 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Multiple Myeloma × Maintenance × Clear all
NCT07029776 2026-03-03

MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma

University of Arkansas

Phase 2 Not yet recruiting
50 enrolled
Plasma cell

Multiple Myeloma

NCT06744894 2024-12-20

SIL as Maintenance Therapy in Multiple Myeloma

Navy General Hospital, Beijing

Phase 2 Not yet recruiting
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡